Hypertension Journal

Register      Login

VOLUME 2 , ISSUE 4 ( October-December, 2016 ) > List of Articles

RESEARCH ARTICLE

Clinical Implications of Recent Therapeutic Trials in Hypertension: Insights from SPRINT and HOPE-3 Trials

Prakash Deedwania, Tushar Acharya

Citation Information : Deedwania P, Acharya T. Clinical Implications of Recent Therapeutic Trials in Hypertension: Insights from SPRINT and HOPE-3 Trials. Hypertens J 2016; 2 (4):194-199.

DOI: 10.5005/jp-journals-10043-0055

Published Online: 00-12-2016

Copyright Statement:  Copyright © 2016; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

How to cite this article

Deedwania P, Acharya T. Clinical Implications of Recent Therapeutic Trials in Hypertension: Insights from SPRINT and HOPE-3 Trials. Hypertens J 2016;2(4):194-199.


PDF Share
  1. Global burden of hypertension: analysis of worldwide data. Lancet 2005 Jan 15-21; 365(9455):217-223.
  2. Heart Disease and Stroke Statistics-2016 update: a report from the American Heart Association. Circulation 2016 Jna 26;133(4):e38–e360.
  3. Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. J Hypertens 2014 Jun;32(6):1170-1177.
  4. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010:a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012 Dec 15;380(9859):2224-2260.
  5. here Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013:a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015 Dec 5;386(10010):2287-2323.
  6. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003 Nov 8;362(9395):1527-1535.
  7. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000 Dec 9;356(9246):1955-1964.
  8. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14;360(9349):1903-1913.
  9. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA 1991 Jan 23-30; 265(4):489-495.
  10. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006 Jun 20;144(12):884-893.
  11. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003 May 21;289(19): 2560-2572.
  12. Evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014 Feb 5;311(5):507-520.
  13. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med 2014 Apr 1;160(7):499-503.
  14. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 2014 Oct;11(5):532-546.
  15. SPRINT Research Group, A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015 Nov 26;373(22):2103-2116.
  16. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016 May 26;374(21):2009-2020.
  17. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 Dec 18;288(23):2981-2997.
  18. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012 Jun;59(6):1110-1117.
  19. Efficacy of low-dose chlorthalidone and hydrochlorothiazide as assessed by 24-h ambulatory blood pressure monitoring. J Am Coll Cardiol 2016 Feb 2;67(4):379-389.
  20. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012 Aug;33(16):2088-2097.
  21. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 2014 May;174(5):773-785.
  22. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ?75 years: a randomized clinical trial. JAMA 2016 Jun 28;315(24):2673-2682.
  23. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet 2016 Aug 26. pii: S0140-6736(16)31326-5.
  24. Unattended blood pressure measurements in the systolic blood pressure intervention trial: implications for entry and achieved blood pressure values compared with other trials. Hypertension 2016 May;67(5):808-812.
  25. Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients. Blood Press 2016 Aug;25(4):228-234.
  26. The implications of blood pressure measurement methods on treatment targets for blood pressure. Circulation 2016 Sep 27;134(13):904-905.
  27. SPRINT proves that lower is better for nondiabetic high-risk patients, but at a price. Am J Hypertens 2016 Jan;29(1):2-4.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.